Article thumbnail

Role of Factor VII in Correcting Dilutional Coagulopathy and Reducing Re-operations for Bleeding Following Non-traumatic Major Gastrointestinal and Abdominal Surgery

By Thomas C. Tsai, James H. Rosing and Jeffrey A. Norton
Topics: Original Article
Publisher: Springer-Verlag
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A 43-year-old man was admitted to the hospital with the diagnosis of acute pancreatitis of 4 days' duration.
  2. A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study.
  3. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high dose-activated factor VII. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S61–S65.
  4. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch Surg 1997;132(6):620–624. Discussion
  5. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly.
  6. (2010). Early urgent relaparotomy. Arch Surg 1984;119(4):369–374. J Gastrointest Surg
  7. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial.
  8. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg 2008;143(3):296–304; discussion 304.
  9. (2005). Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med
  10. Hemorrhage after pancreatoduodenectomy.
  11. Hemphill JC 3rd et al. Multidisciplinary approach to the challenge of hemostasis.
  12. (2002). Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med
  13. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients.
  14. Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective.
  15. Management of delayed postoperative hemorrhage after pancreaticoduodenectomy: a metaanalysis. Arch Surg 2008;143(10):1001–1007. Discussion
  16. (2006). Management of early hemorrhage from pancreatic anastomoses after pancreaticoduodenectomy. Dig Surg
  17. (2010). Massive transfusion protocols: the role of aggressive resuscitation versus product ratio in mortality reduction.
  18. Postpancreatectomy hemorrhage: diagnosis and treatment: an analysis in 1669 consecutive pancreatic resections.
  19. Prevention and treatment of major blood loss.
  20. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.
  21. Recombinant activated factor VII in cardiac surgery: a meta-analysis.
  22. (2008). Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care
  23. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, doubleblind clinical trials.
  24. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation.
  25. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev.
  26. Recombinant FVIIa in the management of uncontrolled hemorrhage.
  27. (2009). Recombinat activated factor VII following pediatric cardiac surgery.
  28. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding—a European perspective.
  29. (2010). Reoperation for early postoperative complications after gastric cancer surgery in a Chinese hospital.
  30. Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case report.
  31. The continuing risk of transfusion-transmitted infections.
  32. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.
  33. The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagul Fibrinolysis 2000;11(Suppl 1):S129–S132.
  34. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery. Ann Thorac Surg 2008;85(5):1669–1676. discussion 1676–1667.
  35. Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients.